Reading Time: 2 minutesThis week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Category: Treatments
Reading Time: 3 minutesA recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug
Reading Time: 5 minutesLast Thursday marked an exciting milestone in the search for effective therapies for MND as full results from the early-phase 1/2 trial of Biogen’s tofersen
Reading Time: 4 minutesAlthough ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in
Reading Time: 5 minutesThis blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 4 minutesThis blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and
Reading Time: 3 minutesTUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure
Reading Time: 5 minutesThere are literally thousands of websites on the internet that make claims about amazing alternative or off-label treatments (AOTs) and even cures for MND but
Reading Time: 2 minutesThis article was written by Dr Keith Mayl and Dr Ahmad Al Khleifat of King’s College London. Researchers at King’s College Hospital, led by Professor
Causes and disease mechanisms Clinical Trials Markers of Disease Progression MND Research Models of MND Research we fund Treatments
How animals are helping to improve our understanding of MND
Reading Time: 6 minutes‘From antibiotics and insulin to blood transfusions and treatments for cancer or HIV, virtually every medical achievement in the past century has depended directly or